Literature DB >> 8387763

Neurotensin regulates growth of human pancreatic cancer.

J Ishizuka1, C M Townsend, J C Thompson.   

Abstract

OBJECTIVE: The effect of neurotensin (NT) on in vitro-growth of human pancreatic cancer cells (MIA PaCa-2) was examined. Furthermore, the intracellular signal-transduction pathways by which neurotensin regulates growth of MIA PaCa-2 cells were determined. SUMMARY BACKGROUND DATA: NT is trophic for normal rat pancreas, but the effect of NT on growth of human pancreatic cancer is not known.
METHODS: Effects of NT (10(-12) to 10(-6) mol/l) on growth of MIA PaCa-2 cells were determined by both count of cell numbers and 3H-thymidine incorporation. Action of NT on phosphatidylinositol (PI) hydrolysis, cyclic AMP production, and intracellular calcium level were determined by conventional methods. The effects of 8-bromo-cyclic AMP and prostaglandin E2 on cell growth were determined.
RESULTS: Low concentrations of NT (10(-12) to 10(-9) mol/l) stimulated growth in a dose-dependent manner, but higher concentrations of NT (10(-8) to 10(-6) mol/l) did not stimulate growth of MIA PaCa-2 cells. NT (10(-12) to 10(-6) mol/l) stimulated PI hydrolysis and increased intracellular calcium levels in a dose-dependent manner. High concentrations of NT (10(-8) to 10(-6) mol/l) stimulated production of cyclic AMP in a dose-dependent manner. 8-bromo-cyclic AMP inhibited growth of MIA PaCa-2 cells; prostaglandin E2 did not affect growth of MIA PaCa-2 cells.
CONCLUSIONS: NT stimulates growth of MIA PaCa-2 cells through stimulation of PI hydrolysis and mobilization of calcium. Stimulation of the cyclic AMP pathway by high concentrations of NT abolishes the growth-stimulatory effect of NT that is mediated through PI hydrolysis or calcium mobilization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387763      PMCID: PMC1242817          DOI: 10.1097/00000658-199305010-00003

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  38 in total

1.  Convenient elimination of trichloroacetic acid prior to radioimmunoassay of cyclic nucleotides.

Authors:  C Tihon; M B Goren; E Spitz; H V Rickenberg
Journal:  Anal Biochem       Date:  1977-06       Impact factor: 3.365

2.  Effects of neurotensin on the isolated mouse distal colon.

Authors:  J Fontaine; P Lebrun
Journal:  Eur J Pharmacol       Date:  1985-01-02       Impact factor: 4.432

3.  Inhibition of gastric and intestinal motor activity in dogs by (Gln4) neurotensin.

Authors:  S Andersson; S Rosell; U Hjelmquist; D Chang; K Folkers
Journal:  Acta Physiol Scand       Date:  1977-06

4.  The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami.

Authors:  R Carraway; S E Leeman
Journal:  J Biol Chem       Date:  1973-10-10       Impact factor: 5.157

5.  Distribution of neurotensin in the canine gastrointestinal tract.

Authors:  H Doyle; G H Greeley; L Mate; T Sakamoto; C M Townsend; J C Thompson
Journal:  Surgery       Date:  1985-03       Impact factor: 3.982

6.  A new generation of Ca2+ indicators with greatly improved fluorescence properties.

Authors:  G Grynkiewicz; M Poenie; R Y Tsien
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

7.  Molecular properties of neurotensin receptors in rat brain. Identification of subunits by covalent labeling.

Authors:  J Mazella; P Kitabgi; J P Vincent
Journal:  J Biol Chem       Date:  1985-01-10       Impact factor: 5.157

8.  Role of neurotensin in pancreatic secretion.

Authors:  T Sakamoto; J Newman; M Fujimura; G H Greeley; C M Townsend; J C Thompson
Journal:  Surgery       Date:  1984-08       Impact factor: 3.982

Review 9.  Inositol trisphosphate, a novel second messenger in cellular signal transduction.

Authors:  M J Berridge; R F Irvine
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

10.  Neurotensin increases colonic motility.

Authors:  K Thor; S Rosell
Journal:  Gastroenterology       Date:  1986-01       Impact factor: 22.682

View more
  16 in total

Review 1.  Protein kinase D enzymes: novel kinase targets in pancreatic cancer.

Authors:  Geou-Yarh Liou; Peter Storz
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-07-17       Impact factor: 3.869

2.  Neurotensin receptor 1 overexpression in inflammatory bowel diseases and colitis-associated neoplasia.

Authors:  Xianyong Gui; Shuhong Liu; Yuchu Yan; Zuhua Gao
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

3.  Gut peptide receptor expression in human pancreatic cancers.

Authors:  R A Ehlers; Sh Kim; Y Zhang; R T Ethridge; C Murrilo; M R Hellmich; D B Evans; C M Townsend; B Mark Evers
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

4.  Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24.

Authors:  C Poinot-Chazel; M Portier; M Bouaboula; N Vita; F Pecceu; D Gully; J G Monroe; J P Maffrand; G Le Fur; P Casellas
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

Review 5.  GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.

Authors:  Krishna Sriram; Cristina Salmerón; Shu Z Wiley; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

6.  Neurotensin signaling induces intracellular alkalinization and interleukin-8 expression in human pancreatic cancer cells.

Authors:  Ulrike Olszewski; Gerhard Hamilton
Journal:  Mol Oncol       Date:  2009-02-03       Impact factor: 6.603

7.  [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results.

Authors:  Theodosia Maina; Anastasia Nikolopoulou; Eleni Stathopoulou; Athanassios S Galanis; Paul Cordopatis; Berthold A Nock
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-27       Impact factor: 9.236

8.  Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma.

Authors:  J C Reubi; B Waser; H Friess; M Büchler; J Laissue
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

Review 9.  Progress toward hormonal therapy of gastrointestinal cancer.

Authors:  R J Bold; J Ishizuka; C M Townsend
Journal:  Ann Surg       Date:  1996-01       Impact factor: 12.969

10.  Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.

Authors:  Carolien Boeckx; Lina Blockx; Ken Op de Beeck; Ridha Limame; Guy Van Camp; Marc Peeters; Jan B Vermorken; Pol Specenier; An Wouters; Marc Baay; Filip Lardon
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.